The Conversation (0)
Sierra Oncology announced the new appointment of Dr. Andrew Allen to its board of directors.
Sierra Oncology (NASDAQ:SRRA) announced the new appointment of Dr. Andrew Allen to its board of directors.
As quoted in the press release:
“With the proven success of PARP inhibitors in treating cancer, significant attention has been focused on identifying and advancing the next-generation of targeted therapeutics that leverage the DNA damage response,” said Dr. Allen. “I’ve been highly encouraged by the sophisticated approach Sierra is taking to developing SRA737, leveraging the rich biology of Chk1 synthetic lethality to incorporate prospective genomic profiling strategies to enhance patient selection in their trials and potentially improve their prospects for positive outcomes. I look forward to working closely with this outstanding team.”
“Andrew Allen’s experience and exemplary track record of success in oncology drug development are highly aligned with the vision at Sierra Oncology to build a commercial company delivering impactful therapeutics for patients with cancer,” added Mr. Donald Parfet, Chairman of the Board of Directors of Sierra Oncology.
Click here to read the full press release.
Source: www.newswire.ca
